軟組織生物製品管道 - 發展階段、細分市場、地區和國家、監管途徑、主要參與者（2024 年版）

該報告檢查和分析了軟組織生物製品管道產品，並提供了全面的信息，包括不同開發階段的產品的比較分析和正在進行的臨床試驗的數據。

目錄

第1章 目錄

第2章簡介

第3章 開發中產品

• 軟組織生物製品 - 管道產品：依開發階段劃分
• 軟組織生物製劑 - 管道產品：按細分市場
• 軟組織生物製品 - 管道產品：按地區
• 軟組織生物製品 - 管道產品：依監管途徑
• 軟組織生物製品 - 管道產品：按預計批准日期
• 軟組織生物製劑 - 正在進行的臨床試驗

第4章 軟組織生物製劑－各公司在研產品

• 軟組織生物製品公司 - 管道產品：依開發階段
• 軟組織生物製品 - 管道產品：依開發階段劃分

第5章 軟組織生物製品公司及產品概述

• Acuitive Technologies Inc：公司概況
  • Acuitive Technologies Inc：管道產品和正在進行的臨床試驗概述
• Anika Therapeutics Inc：公司概況
  • Anika Therapeutics Inc：管道產品和正在進行的臨床試驗概述
• BioGend Therapeutics 有限公司：公司概況
  • BioGend Therapeutics Co Ltd：管道產品和正在進行的臨床試驗概述
• Colorado Therapeutics, LLC：公司概況
  • Colorado Therapeutics, LLC：管道產品和正在進行的臨床試驗概述
• Columbia University：公司概況
  • Columbia University：管道產品和正在進行的臨床試驗概述
• Core Essence Orthopedics, LLC：公司概況
  • Core Essence Orthopedics, LLC：管道產品和正在進行的臨床試驗概述
• Georgia Institute of Technology：公司概況
  • Georgia Institute of Technology：管道產品和正在進行的臨床試驗概述
• New York R&D Center for Translational Medicine and Therapeutics Inc：公司概況
  • New York R&D Center for Translational Medicine and Therapeutics Inc：管道產品和正在進行的臨床試驗概述
• Nutech Medical Inc：公司概況
  • Nutech Medical Inc：管道產品和正在進行的臨床試驗概述
• OHSU Knight Cancer Institute：公司簡介
  • OHSU Knight Cancer Institute：管道產品和正在進行的臨床試驗概述
• Osteopore International Pte Ltd：公司概況
  • Osteopore International Pte Ltd：管道產品和正在進行的臨床試驗概述
• Shandong Junxiu Biotechnology Co Ltd：公司概況
  • Shandong Junxiu Biotechnology Co Ltd：在研產品概況及正在進行的臨床試驗
• STEL Technologies LLC：公司概況
  • STEL Technologies LLC：管道產品和正在進行的臨床試驗概述
• Tissue Regenix Group PLC：公司概況
  • Tissue Regenix Group PLC：管道產品和正在進行的臨床試驗概述
• University of Arizona：公司概況
  • University of Arizona：管道產品和正在進行的臨床試驗概述
• University of Bielefeld：公司概況
  • University of Bielefeld：管道產品和正在進行的臨床試驗概述
• University of Minnesota：公司概況
  • University of Minnesota：管道產品和正在進行的臨床試驗概述
• University of Missouri：公司概況
  • University of Missouri：管道產品和正在進行的臨床試驗概述
• University of Zurich：公司概況
  • University of Zurich：管道產品和正在進行的臨床試驗概述

第6章 軟組織生物製品 - 最新進展

• 2024 年 8 月 27 日：Chinese Academy of Sciences，3D 生物列印材料具有改善骨骼和軟組織修復的潛力
• 2024 年 8 月 12 日：Biorez、BioBrace Reinforced Implant獲得 510(K) 批准
• 2024 年 6 月 11 日：Allosource 推出 Aceconnex，這是首款用於髖關節盂唇重建和加強的縫合筋膜裝置
• 2024 年 5 月 2 日：Organogenesis，膝關節炎治療 ReNu 3 期臨床試驗達成主要評價項目
• 2023 年 11 月 2 日：Humacyte 於 2023 年 11 月 9 日公佈第三季財務業績，並提供公司最新動態
• 2023 年 10 月 31 日：案例研究顯示 BioTissue 的創新人類羊膜同種異體移植物可有效治療複雜的足部潰瘍和創傷

第7章附錄

GlobalData's Medical Devices sector report, "Soft Tissue Biologics Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Soft Tissue Biologics pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Soft Tissue Biologics are used in surgical procedures to replace, reinforce, or repair tendons or ligaments that have been torn or damaged in the human body. Soft Tissue Biologics market focuses on the repair of the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL), rotator cuff, and Achilles's tendon.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the Soft Tissue Biologics under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Soft Tissue Biologics and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Soft Tissue Biologics under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Soft Tissue Biologics Overview

3 Products under Development

• 3.1 Soft Tissue Biologics - Pipeline Products by Stage of Development
• 3.2 Soft Tissue Biologics - Pipeline Products by Segment
• 3.3 Soft Tissue Biologics - Pipeline Products by Territory
• 3.4 Soft Tissue Biologics - Pipeline Products by Regulatory Path
• 3.5 Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
• 3.6 Soft Tissue Biologics - Ongoing Clinical Trials

4 Soft Tissue Biologics - Pipeline Products under Development by Companies

• 4.1 Soft Tissue Biologics Companies - Pipeline Products by Stage of Development
• 4.2 Soft Tissue Biologics - Pipeline Products by Stage of Development

5 Soft Tissue Biologics Companies and Product Overview

• 5.1 Acuitive Technologies Inc Company Overview
  • 5.1.1 Acuitive Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 Anika Therapeutics Inc Company Overview
  • 5.2.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.3 BioGend Therapeutics Co Ltd Company Overview
  • 5.3.1 BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.4 Colorado Therapeutics, LLC Company Overview
  • 5.4.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.5 Columbia University Company Overview
  • 5.5.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
• 5.6 Core Essence Orthopaedics, LLC Company Overview
  • 5.6.1 Core Essence Orthopaedics, LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.7 Georgia Institute of Technology Company Overview
  • 5.7.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
• 5.8 New York R&D Center for Translational Medicine and Therapeutics Inc Company Overview
  • 5.8.1 New York R&D Center for Translational Medicine and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.9 Nutech Medical Inc Company Overview
  • 5.9.1 Nutech Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
• 5.10 OHSU Knight Cancer Institute Company Overview
  • 5.10.1 OHSU Knight Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview
• 5.11 Osteopore International Pte Ltd Company Overview
  • 5.11.1 Osteopore International Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.12 Shandong Junxiu Biotechnology Co Ltd Company Overview
  • 5.12.1 Shandong Junxiu Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
• 5.13 STEL Technologies LLC Company Overview
  • 5.13.1 STEL Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.14 Tissue Regenix Group PLC Company Overview
  • 5.14.1 Tissue Regenix Group PLC Pipeline Products & Ongoing Clinical Trials Overview
• 5.15 University of Arizona Company Overview
  • 5.15.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview
• 5.16 University of Bielefeld Company Overview
  • 5.16.1 University of Bielefeld Pipeline Products & Ongoing Clinical Trials Overview
• 5.17 University of Minnesota Company Overview
  • 5.17.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
• 5.18 University of Missouri Company Overview
  • 5.18.1 University of Missouri Pipeline Products & Ongoing Clinical Trials Overview
• 5.19 University of Zurich Company Overview
  • 5.19.1 University of Zurich Pipeline Products & Ongoing Clinical Trials Overview

6 Soft Tissue Biologics- Recent Developments

• 6.1 Aug 27, 2024: Chinese Academy of Sciences : 3D Bioprinting Materials Offer Possibility for Better Bone and Soft Tissue Repair
• 6.2 Aug 12, 2024: Biorez Receives 510(K) Clearance for BioBrace Reinforced Implant
• 6.3 Jun 11, 2024: Allosource Launches Aceconnex, First Pre-sutured Fascia Device for Hip Labral Reconstruction and Augmentation
• 6.4 May 02, 2024: Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
• 6.5 Nov 02, 2023: Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
• 6.6 Oct 31, 2023: BioTissue's Innovative Human Amniotic Allografts Show Efficacy in Treating Complex Foot Ulcers and Traumatic Wounds in Case Studies

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer

List of Tables

• Soft Tissue Biologics - Pipeline Products by Stage of Development
• Soft Tissue Biologics - Pipeline Products by Segment
• Soft Tissue Biologics - Pipeline Products by Territory
• Soft Tissue Biologics - Pipeline Products by Regulatory Path
• Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
• Soft Tissue Biologics - Ongoing Clinical Trials
• Soft Tissue Biologics Companies - Pipeline Products by Stage of Development
• Soft Tissue Biologics - Pipeline Products by Stage of Development
• Glossary

List of Figures

• Soft Tissue Biologics - Pipeline Products by Stage of Development
• Soft Tissue Biologics - Pipeline Products by Segment
• Soft Tissue Biologics - Pipeline Products by Territory
• Soft Tissue Biologics - Pipeline Products by Regulatory Path
• Soft Tissue Biologics - Pipeline Products by Estimated Approval Date
• Soft Tissue Biologics - Ongoing Clinical Trials